Cam Gallagher, Director at Zentalis Pharmaceuticals, Inc. (ZNTL), sold 19,900 shares at $51.59 ($1.0M) on 2022-04-05, disclosed to the SEC on 2022-04-05.
Open-market sale of $1.0M ZNTL by Director. Not flagged as scheduled, tax-driven, or recurring — but no specific bearish signal from our filters. Reasons for insider sales vary widely.
Nothing distinguishes this filing.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $49.72 | 4,369 | $217K | 21.6% |
| 2 | $49.72 | 4,369 | $217K | 21.6% |
| 3 | $50.68 | 3,335 | $169K | 16.8% |
| 4 | $50.68 | 3,335 | $169K | 16.8% |
| 5 | $51.59 | 2,196 | $113K | 11.3% |
| 6 | $51.59 | 2,196 |
| $113K |
| 11.3% |
| 7 | $52.70 | 100 | $5K | 0.5% |
| Total | $50.47 avg | 19,900 | $1.0M | 100% |
| Filing → |
| ZNTL | SELL | 2024-02-12 | $13K | — | Filing → |
| ZNTL | SELL | 2024-02-05 | $267K | — | Filing → |
| ZNTL | SELL | 2023-05-31 | $1.5M | — | Filing → |